Clinical Trial Update: Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC [Phase 3]

View source ↗

Summary

A Phase 3 trial compares lenvatinib plus sintilimab plus TACE versus lenvatinib plus TACE in non-resectable hepatocellular carcinoma under recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)
• Transarterial chemoembolization (chemotherapy with embolization (various agents))

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 3 | Status: RECRUITING